Pfizer to give data to participants in its studies
7th December 2013
As the debate on data transparency continues, Pfizer has updated its policy “that will simplify and broaden access” to information gathered in its clinical trials.
The drug giant says the move “meets or exceeds” the principles for responsible data sharing issued in July by the Pharmaceutical Research and Manufacturers of America and the European Federation of Pharmaceutical Industries and Associations. Its INSPIIRE public web portal for investigator-initiated research will “offer qualified researchers a standard form and process for requesting access to anonymised patient-level data from Pfizer-sponsored trials of approved (or discontinued) products/indications posted on clinicaltrials.gov that have been complete for 24 months”.